Rachel W. Humphrey, MD

Dr. Rachel W. Humphrey has an extensive work experience in the biotech and pharmaceutical industry. Rachel W. is currently serving as the President and Founding CEO of Normunity since October 2021. In addition, they hold the position of an Independent Board Director at Pyxis Oncology and Sporos Bioventures, starting in August and October 2021 respectively. Dr. Humphrey is also a Scientific Advisory Board Member at Grey Wolf Therapeutics and HotSpot Therapeutics, joining both companies in October and December 2021 respectively.

Before these roles, Dr. Humphrey worked as an Independent Board Director at Xilio Therapeutics, Inc. from September 2019 to June 2022. Rachel W. also held the position of Chief Medical Officer at Black Diamond Therapeutics from September 2020 to September 2021. Rachel W. was a Board Director and Chief Medical Officer at Treadwell Therapeutics, Inc. from January to May 2020, and Head of Research and Development at TIO Bioventures during the same period.

Dr. Humphrey's notable experience also includes their role as the Senior Vice President and Chief Medical Officer at CytomX Therapeutics from August 2015 to September 2019. Prior to that, they briefly served on the company's Board of Directors from March to August 2015.

Based on their work history, it is evident that Dr. Rachel W. Humphrey has held key leadership and advisory roles in various biotech and pharmaceutical companies, showcasing their expertise and contributions to the industry.

Rachel W. Humphrey, MD has an extensive education history. Rachel W. started their academic journey by earning a Bachelor of Arts (BA) degree in Biochemistry from Harvard University, where they studied from 1979 to 1983. Following this, Rachel pursued their medical education at Case Western Reserve University School of Medicine, where they obtained their MD degree during the years 1985 to 1989. Rachel W. further honed their medical skills by completing a Residency in Internal Medicine at The Johns Hopkins University School of Medicine from 1989 to 1992.